Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2020
SABCS 2020
Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine
SABCS 2020 – MBC
,
SABCS 2020
In this study of the impact of tucatinib in patients with HER2-positive metastatic breast cancer with stable and active brain metastases, health-related quality of life was maintained, while significant and clinically meaningful improvement in overall survival was observed.
Read More ›
Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer
SABCS 2020 – MBC
,
SABCS 2020
Interim safety and efficacy analysis of a phase 1b/2 clinical trial of tucatinib, palbociclib, and letrozole in patients with HR-positive and HER2-positive metastatic breast cancer demonstrates antitumor activity and safety profile that warrant future studies.
Read More ›
Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer
SABCS 2020 – MBC
,
SABCS 2020
Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, the addition of tucatinib to trastuzumab and capecitabine showed clinically meaningful improvements in efficacy independent of hormone receptor status.
Read More ›
Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer
SABCS 2020 – MBC
,
SABCS 2020
In this final overall survival analysis of ExteNET, there were fewer deaths with neratinib despite not reaching statistical significance and greater overall survival with neratinib in subgroups.
Read More ›
Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients
SABCS 2020 – MBC
,
SABCS 2020
The healthcare resource utilization of brain metastases is significantly higher among patients with HER2-positive metastatic breast cancer compared with patients without brain metastases, emphasizing the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease.
Read More ›
Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer
SABCS 2020 – MBC
,
SABCS 2020
Geriatric patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, highlighting the need for prospective studies to improve outcomes.
Read More ›
Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy
SABCS 2020 – MBC
,
SABCS 2020
The use of circulating tumor cells to monitor HER2 status may help to identify patients who could benefit from a modified treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch.
Read More ›
Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
SABCS 2020 – MBC
,
SABCS 2020
ARX788-211 is a phase 2/3 randomized, multicenter, open-label trial comparing ARX788 with lapatinib and capecitabine in patients with HER2-positive, locally advanced, or metastatic breast cancer.
Read More ›
HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer
SABCS 2020 – MBC
,
SABCS 2020
To evaluate the use of tucatinib with T-DM1 for unresectable locally advanced or metastatic HER2-positive breast cancer, enrollment for the HER2CLIMB-02 trial is ongoing in the United States and planned internationally.
Read More ›
NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib
SABCS 2020 – MBC
,
SABCS 2020
Patients with HER2-positive metastatic breast cancer treated with ≥2 lines of HER2-directed therapy had better outcomes in the neratinib plus capecitabine arm compared with the lapatinib plus capecitabine arm irrespective of the baseline status of CNS metastases.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us